The World Health Organization said Friday it has granted its first authorization for use of a vaccine against mpox in adults, calling it an important step toward fighting the disease in Africa.
The approval of the vaccine made by Bavarian Nordic A/S means that donors like vaccines alliance Gavi and UNICEF can buy it. But supplies are limited because there’s only a single manufacturer.
“This first (authorization) of a vaccine against mpox is an important step in our fight against the disease, both in the context of the current outbreaks in Africa, and in future,” said WHO Director-General Tedros Adhanom Ghebreyesus.
WHO also said it was creating an “access and allocation mechanism” to try to fairly distribute mpox tests, treatments and vaccines to the countries who need them most.
RELATED STORY | Mpox cases nearly double at start of 2024 versus same time last year
The U.N. health agency approved the two-dose mpox vaccine for people aged 18 and above. WHO said that while it was not recommending the vaccine for those under 18, the shot may be used in infants, children and adolescents “in outbreak settings where the benefits of vaccination outweigh the potential risks.”
WHO recommended that a single dose of the shot could be used to stretch supplies, but emphasized the need to collect more data on how effective the vaccine might be as a single shot.
The mpox vaccine made by Bavarian Nordic was previously authorized by numerous rich countries across Europe and North America during the global mpox outbreak in 2022. Millions of doses given to adults showed the vaccine helped slow the virus’ spread, but there is limited evidence of how it works in children.
Officials at the Africa Center for Disease Control and Prevention said last month that nearly 70% of cases in Congo — the country hardest hit by mpox — are in children younger than 15, who also accounted for 85% of deaths.
RELATED STORY | US doctors on guard for strain of mpox spreading in Africa
Overall, WHO said over 120 countries have confirmed more than 103,000 cases of mpox since the outbreak began two years ago. Its latest tally, as of Sunday, showed that 723 people in more than a dozen countries in Africa have died of the disease.
African experts have estimated they might need about 10 million vaccines to stop the ongoing outbreaks on the continent while donor countries have promised to provide about 3.6 million vaccines. As of last week, Congo had received only about 250,000 doses.
On Thursday, the Africa CDC said 107 new deaths and 3,160 new cases had been recorded in the past week, just a week after it and WHO launched a continent-wide response plan.
Mpox belongs to the same family of viruses as smallpox but causes milder symptoms like fever, chills and body aches. People with more serious cases can develop lesions on the face, hands, chest and genitals.
